Celsion (CLSN) in Focus: Stock Adds 5.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 3 mins ago
Celsion Corp. (CLSN) was a big mover last session, as its shares rose over 5% on the day.
Agenus Inc. (AGEN) Looks Strong as Stock Surges 11.15% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 10 mins ago
Agenus Inc. (AGEN) was a big mover last session, as the company saw its shares shoot up over 11% on the day.
Actelion Beats on Q2 Earnings and Sales, Revises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 1:50PM CDT
Actelion LTD. (ALIOF) reported second-quarter earnings of $2.83 per American Depository Receipt (ADR), up 203.77% from the prior-year earnings of 93 cents per ADR, beating the Zacks Consensus Estimate of $1.37 per share.
Jazz Pharmaceuticals/Concert Pharmaceuticals Start Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:25PM CDT
Jazz Pharmaceuticals (JAZZ) and Concert Pharmaceuticals (CNCE) announced the initiation of a phase I study on JZP-386.
European Stocks Rebound as EU Meets to Discuss Russia Sanctions
at The Street - Tue Jul 22, 4:54AM CDT
European stocks rebound Tuesday, as EU foreign ministers gather in Brussels to discuss whether to increase sanctions against Russia.
Actelion delivers strong half year operational and financial results
Thomson Reuters ONE - Tue Jul 22, 1:38AM CDT
Actelion Pharmaceuticals Ltd / Actelion delivers strong half year operational and financial results . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Isis Pharma Initiates Phase II Study on ISIS-APO(a) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 5:50PM CDT
Isis Pharmaceuticals, Inc. (ISIS) initiated a phase II study on ISIS-APO(a) in patients suffering from high lipoprotein(a) -- Lp(a).
Alkermes' Pipeline Development Impresses, Key Updates Ahead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 3:40PM CDT
Alkermes (ALKS) announced the commencement of a phase I study on ALKS 8700.
Amgen's AMG 416 Succeeds in Phase III, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 12:23PM CDT
Amgen Inc. (AMGN) announced that AMG 416 (formerly known as velcalcetide) has met the primary as well as secondary endpoints in a phase III study.
The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
PR Newswire - Mon Jul 21, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH-Free Report), Amgen, Inc. (Nasdaq:AMGN-Free Report), Eli Lilly and Company (NYSE:LLY-Free Report), Actelion Ltd. (OTC:ALIOF-Free Report) and InterMune, Inc. (Nasdaq:ITMN-Free Report).
Ultragenyx (RARE) Jumps: Stock Moves 7.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 21, 8:25AM CDT
Ultragenyx (RARE) was a big mover last session, with shares rising nearly 8% on the day.
Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 5:15PM CDT
Synergy Pharmaceuticals (SGYP) completed patient enrollment for its phase II study on SP-333.
Anthera Acquires Sollpura from Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:20PM CDT
Anthera Pharmaceuticals (ANTH) acquired mid-stage development candidate, Sollpura, from Eli Lilly and Company (LLY).
InterMune's (ITMN) Esbriet Gets Breakthrough Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 4:00PM CDT
InterMune (ITMN) received breakthrough therapy designation for its primary product, Esbriet, from the FDA.
Bristol-Myers/Pfizer Commence Phase IV Study on Eliquis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 18, 3:45PM CDT
Bristol-Myers (BMY) and Pfizer (PFE) Began enrolling patients in a study on Eliquis.
Lannett Shares Down on Subpoena Receipt from Connecticut AG - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 4:10PM CDT
Lannett Company (LCI) has received a subpeona from Connecticut AG.
Rigel Pharmaceuticals Starts Fostamatinib Late Stage Program - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 3:45PM CDT
Rigel Pharma (RIGL) initiated a phase III program on fostamatinib .
Global Insomnia Clinical Trials Review, H2, 2014 Featuring 10 Companies & 10 Institutes
M2 - Thu Jul 17, 8:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xplssq/insomnia_global) has announced the addition of the "Insomnia Global Clinical Trials Review, H2, 2014" report to their offering. Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Insomnia. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Sanofi - Neurocrine Biosciences, Inc. - Pfizer Inc. - GlaxoSmithKline plc - Neurim Pharmaceuticals Ltd - Eisai Co., Ltd. - Actelion Ltd Clinical Trial Overview of Top Institutes / Government - University of Rochester - Duke University - U.S. Department of Veterans Affairs - Karolinska Institute - University of Pittsburgh - Brigham and Women's Hospital - Stanford University - The University of Hong Kong - Massachusetts General Hospital - National Institute of Mental Health For more information visit http://www.researchandmarkets.com/research/xp...nia_global
Ligand Pharmaceuticals (LGND) in Focus: Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jul 17, 7:31AM CDT
Ligand Pharmaceuticals has seen flat earnings estimate revisions for the current year along with a significant decline in its share price for the past month
Theravance/Glaxo Commence Global Late stage Study on COPD - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 5:42PM CDT
Glaxo (GSK) and Theravance (THRX) initiated a phase III study in COPD.